Barriers and facilitators to deprescribing antithrombotic therapy in advanced cancer patients: A qualitative interview study of patients’, companions’ and clinicians’ experiences and perspectives
- Conditions
- Cancer and deprescribing antithrombotic therapy at end-of-lifeNot Applicable
- Registration Number
- ISRCTN18388825
- Lead Sponsor
- Cardiff University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 39
Patients:
1. Aged 18 years old and over
2. Advanced cancer (whose life expectancy is less than one year, according to the healthcare professional identifying eligible participants)
3. Receiving antithrombotic medicine for one of the following diseases: atrial fibrillation/stroke prevention, mechanical heart valve, peripheral vascular disease, and deep vein thrombosis or pulmonary embolus
4. Capacity to give informed consent
5. Capacity to undertake an interview in English
Companions:
1. Companions are defined as person(s) who look after and/or support the patient as identified and chosen by the patient to take part alongside them, should the companion wish to do so
2. Aged 18 years old and over
3. Capacity to give informed consent
4. Capacity to undertake an interview in English
Clinicians:
Clinicians practising in their chosen speciality for 10 years or more, from across the following specialities: oncology, care of the elderly, frailty, stroke medicine, palliative/hospice care, family physician/general practice, cardiology, respiratory medicine, and vascular surgery
Patients and companions:
1. Cognitive impairment
2. Unable to speak or understand English
3. Considered too unwell to participate in a 30-60 minute interview
Study & Design
- Study Type
- Other
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Outcome variables are measured using a 30-60 minute interview at one time point:<br>1. Cancer patients’ (and companions’ if present) experiences, values, and perspectives on antithrombotic therapy measured using a semi-structured interview guide<br>2. Clinicians’ experiences of the current practice of continuing and deprescribing antithrombotic therapy to cancer patients, and their perceptions of key facilitators and barriers to deprescribing measured using a semi-structured interview guide
- Secondary Outcome Measures
Name Time Method There are no secondary outcome measures